ProCE Banner Activity

CME

Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies

Conference Coverage
Text Module

Review expert perspectives and insights on the most clinically relevant data for ovarian, endometrial, and cervical cancers presented at the 2022 SGO, ASCO, ESMO, IGCS, and ESGO meetings.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: January 23, 2023

Expiration: January 22, 2024

No longer available for credit.

Share

Faculty

Susana Banerjee

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Jubilee Brown

Jubilee Brown, MD

Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Elisabeth Diver

Elisabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

David Scott Miller

David Scott Miller, MD, FACOG, FACS

Professor of Obstetrics & Gynecology
Dallas Foundation Chair in Gynecologic Oncology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Parkland Health & Hospital System
Dallas, Texas

Mansoor Raza Mirza

Mansoor Raza Mirza, MD

Medical Director
Department of Oncology
Chief Oncologist
The Finsen Centre
Rigshospitalet
Copenhagen University Hospital
Copenhagen, Denmark

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Angeles Alvarez Secord

Angeles Alvarez Secord, MD, MHSc

Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

Target Audience

This educational program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who treat patients with gynecologic cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in selecting individualized treatment regimens for patients with gynecologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data in cervical, endometrial, and ovarian cancers to clinical practice to expand treatment options and improve outcomes for patients with gynecologic malignancies

  • Assess appropriate predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
  • Evaluate available practice-changing clinical data on new targeted therapies as single-agent or combination therapies in cervical, endometrial, and ovarian cancers
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability, AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp and Dohme, Zentalis; researcher: Apmonia, AstraZeneca.

Angeles Alvarez Secord, MD, MHSc: consultant: Eisai, Myriad; researcher: AbbVie, AstraZeneca, Boehringer Ingelheim, Clovis, Eisai, Immutep, Merck, OncoQuest, PharmaMar, Roche/Genentech, Seagen, Tesaro/ GlaxoSmithKline, VBL.

Jubilee Brown, MD: consultant/advisor/speaker: AstraZeneca, Caris, Clovis, Eisai, GlaxoSmithKline/Tesaro.

Elisabeth Diver, MD: consultant: Curio, EMD Serono, GlaxoSmithKline, Novartis, Onclive, Survivornet; researcher: Aravive, EMD Serono, GlaxoSmithKline.

David Scott Miller, MD, FACOG, FACS: consultant: AbbVie, AstraZeneca, Eisai, Eisai Europe, EMD Serono, GlaxoSmithKline, Incyte, iTeos Belgium, Myriad, Novocure, Seagen, Tarveda, Tesaro; researcher: Advenchen, Agenus, Akesobio, EMD Serono, Karyopharm, Merck Sharp and Dohme, Novocure, Tesaro. 

Prof Isabelle Ray-Coquard, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp and Dohme.

Susana Banerjee, MBBS, MA, PhD, FRCP: consultant/advisor/speaker: Amgen, AstraZeneca, Clovis, EMD Serono, Epsilogen, GlaxoSmithKline, ImmunoGen, Merck Sharp and Dohme Corp, Mersana Therapeutics, Novartis, OncXerna, Pfizer, Regeneron, Roche, Seagen, Shattuck Lans, Takeda.

Mansoor Raza Mirza, MD: advisor/speaker: AstraZeneca, Boehringer Ingelheim, BioCad, GlaxoSmithKline, Karyopharm, Merck, Roche, Zailab; member of board of directors: Karyopharm; stock/stock options: Karyopharm.

Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme, Novartis, Seagen, Sutro. 

Ignace Vergote, MD, PhD: consultant/advisor/speaker: Agenus, Akesobio, AstraZeneca, Bristol-Myers Squibb, Deciphera, Eisai, Elevar Therapeutics, Exelixis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, Immunogen, Jazz, Karyopharm, Mersana, Merck Sharp and Dohme, Novartis, Novocure, Oncoinvent, OncXerna, Regeneron, Sanofi, Seagen, Sotio, Verastem Oncology, Zentalis; researcher: Amgen, Oncoinvent AS, Roche.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 23, 2023, through January 22, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

 

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.